A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy

Neuromuscular Disorders

Volumn 16, Issue 7, 2006, Pages 417-426

  Krosschell, Kristin J ^a   Maczulski, Jo Anne ^b   Crawford, Thomas O ^c   Scott, Charles ^d   Swoboda, Kathryn J ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Johns Hopkins University ^*  (United States)

^c JOHNS HOPKINS CHILDREN S CENTER   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Functional outcome measure; Spinal muscular atrophy

Indexed keywords

ARTICLE; CHILD; DATA ANALYSIS; FUNCTIONAL ASSESSMENT; HUMAN; INFANT; INTERRATER RELIABILITY; INTRARATER RELIABILITY; MAJOR CLINICAL STUDY; MOBILIZATION; MOTOR PERFORMANCE; PEDIATRICS; PRIORITY JOURNAL; RATING SCALE; RELIABILITY; SAMPLE; SPINAL MUSCULAR ATROPHY; STANDARD; TEST RETEST RELIABILITY;

CHILD, PRESCHOOL; CONTRACTURE; DISABILITY EVALUATION; HUMANS; INFANT; MALE; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD; VIDEOTAPE RECORDING;

EID: 33746355222     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2006.03.015     Document Type: Article

References (37)

1. Andreassi C., Angelozzi C., Tiziano F.D., et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 12 1 (2004) 59-65
2. Brahe C., Vitali T., Tiziano F.D., et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 13 2 (2005) 256-259
3. Crawford T.O. Concerns about the design of clinical trials for spinal muscular atrophy. Neuromuscul Disord 14 8-9 (2004) 456-460
4. Beenakker E.A., van der Hoeven J.H., Fock J.M., and Maurits N.M. Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry. Neuromuscul Disord 11 5 (2001) 441-446
5. Merlini L., Solari A., Vita G., et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol 18 8 (2003) 537-541
6. Miller R.G., Moore D.H., Dronsky V., et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 191 1-2 (2001) 127-131
7. Merlini L., Mazzone E.S., Solari A., and Morandi L. Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve 26 1 (2002) 64-70
8. Merlini L., Bertini E., Minetti C., et al. Motor function-muscle strength relationship in spinal muscular atrophy. Muscle Nerve 29 4 (2004) 548-552
9. Sloan C. Review of the reliability and validity of myometry with children. Phys Occup Ther Pediatr 22 2 (2002) 79-93
10. Main M., Kairon H., Mercuri E., and Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 7 4 (2003) 155-159
11. Chung B.H., Wong V.C., and Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics 114 5 (2004) e548-e553
12. Iannaccone S.T. Outcome measures for pediatric spinal muscular atrophy. Arch Neurol 59 9 (2002) 1445-1450
13. Rudnik-Schoneborn S., Hausmanowa-Petrusewicz I., Borkowska J., and Zerres K. The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol 45 3 (2001) 174-181
14. Russman B.S., Buncher C.R., White M., Samaha F.J., and Iannaccone S.T. Function changes in spinal muscular atrophy II and III. The DCN/SMA group. Neurology 47 4 (1996) 973-976
15. Moxley III R.T. Functional testing. Muscle Nerve 13 (1990) S26-S29
16. Vignos Jr. P.J., Spencer Jr. G.E., and Archibald K.C. Management of progressive muscular dystrophy in childhood. J Am Med Assoc 184 (1963) 89-96
17. Brooke M.H., Griggs R.C., Mendell J.R., Fenichel G.M., Shumate J.B., and Pellegrino R.J. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 4 3 (1981) 186-197
18. Brooke M.H., Griggs R.C., Mendell J.R., Fenichel G.M., and Shumate J.B. The natural history of Duchenne muscular dystrophy: a caveat for therapeutic trials. Trans Am Neurol Assoc 106 (1981) 195-199
19. Scott O.M., Hyde S.A., Goddard C., and Dubowitz V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve 5 4 (1982) 291-301
20. Steffensen B., Hyde S., Lyager S., and Mattsson E. Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int 6 3 (2001) 119-134
21. Cedarbaum J.M., Stambler N., Malta E., et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci 169 1-2 (1999) 13-21
22. Cedarbaum J.M., and Stambler N. Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials. J Neurol Sci 152 Suppl 1 (1997) S1-S9
23. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol 44 8 (1987) 812-817
24. Connolly A.M., Schierbecker J., Renna R., and Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 12 10 (2002) 917-925
25. Fenichel G.M., Florence J.M., Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41 12 (1991) 1874-1877
26. Fenichel G.M., Griggs R.C., Kissel J., et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 56 8 (2001) 1075-1079
27. Swoboda K.J., Prior T.W., Scott C.B., et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 57 5 (2005) 704-712
28. Piper M.C., Pinnell L.E., Darrah J., Maguire T., and Byrne P.J. Construction and validation of the Alberta infant motor scale (AIMS). Can J Public Health 83 Suppl 2 (1992) S46-S50
29. Egan D.F., Illingworth R.S., and Mac Keith R.C. Developmental screening 0-5 years, clinics in developmental medicine (1969), Spastic International Medical Publications, London
30. Folio M.R., and Fewell R.R. Peabody developmental motor scales: examiner's manual. 2nd ed. (2000), Pro-Ed, Austin, TX
31. Shrout P.E., and Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86 (1979) 420-428
32. Portnoy L.G., and Watkins M.P. Foundations of clinical research: applications to practice. 1st ed. (1993), Appleton & Lange, Norwalk, CT
33. Castorr A.H., Thompson K.O., Ryan J.W., Phillips C.Y., Prescott P.A., and Soeken K.L. The process of rater training for observational instruments: implications for interrater reliability. Res Nurs Health 13 5 (1990) 311-318
34. Haller K.B. Interrater reliability: essential for research and practice. MCN Am J Mater Child Nurs 12 1 (1987) 78
35. Ryan J.W., Phillips C.Y., and Prescott P.A. Interrater reliability: the underdeveloped role of rater training. Appl Nurs Res 1 3 (1988) 148-150
36. Backman C., and Mackie H. Arthritis hand function test: inter-rater reliability among self-trained raters. Arthritis Care Res 8 1 (1995) 10-15
37. Washington C.C., and Moss M. Pragmatic aspects of establishing interrater reliability in research. Nurs Res 37 3 (1988) 190-191